Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 12, 2007. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the SmithKline Beecham Mid-Term Incentive Plan.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is the transaction price of $54.67 per American Depositary Receipt (ADR).
Material Changes
There are no material changes to the company's financial position or operations reported in this document. The filing details an increase in shareholdings for specific individuals following the re-investment of dividends paid on January 4, 2007.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, risk factors, or contingencies. It strictly reports on the compliance notification of share transactions pursuant to Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).
Key Facts for Investors
- Transaction Type: Increase in Ordinary Share ADR interests via dividend re-investment.
- Transaction Price: $54.67 per ADR.
- Participants: Dr. JP Garnier (1,431.16 ADRs), Dr. F Calhoun (146.28 ADRs), Mr. D Phelan (276.03 ADRs), and Mr. D Stout (110.33 ADRs).
- Dividend Date: The underlying dividend was paid on January 4, 2007.